Literature DB >> 26886284

Significance and evaluation of anaplastic lymphoma kinase by immunohistochemistry in non-small cell lung cancer.

Shuting Ding1, Nan Liu1, Huanyu Zhao1, Guiyang Jiang1, Xiupeng Zhang1, Enhua Wang2.   

Abstract

We used immunohistochemistry and reverse transcription polymerase chain reaction (RT-PCR) to evaluate anaplastic lymphoma kinase (ALK) protein expression and gene rearrangements, respectively, in 283 cases of wild-type epidermal growth factor receptor (EGFR) non-small cell lung cancer biopsy specimens. Immunohistochemistry was positive for ALK in 52 cases (18.4 %), and there was no significant difference in staining between various monoclonal antibodies (Roche ALK test kit, D5F3, p-ALK, and EML4-ALK). On RT-PCR, 36 cases (12.7 %) were positive for ALK. Immunohistochemistry and RT-PCR were both positive in 35 cases and both negative in 230 cases, and both have a high consistency (265/283, 93.6 %). Including 17 cases, immunohistochemistry was positive but RT-PCR was negative, and in one case, immunohistochemistry was negative but RT-PCR was positive. On fluorescence in situ hybridization (FISH) testing of these 18 cases, only three cases were positive (one RT-PCR was positive; two immunohistochemistry were positive). There is a high prevalence of ALK positivity in wild-type EGFR non-small cell lung cancer. Immunohistochemistry for the detection of ALK gene rearrangements was highly consistent with RT-PCR, and thus, it is a good screening tool but produces false positive results that necessitate further screening by RT-PCR or FISH.

Entities:  

Keywords:  ALK; Immunohistochemistry; Non-small cell lung cancer

Mesh:

Substances:

Year:  2016        PMID: 26886284     DOI: 10.1007/s13277-016-4946-9

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

2.  Diagnosis of EML4-ALK Translocation With FISH, Immunohistochemistry, and Real-time Polymerase Chain Reaction in Patients With Non-Small Cell Lung Cancer.

Authors:  Graciela Cruz-Rico; Alejandro Avilés-Salas; Manuel Segura-González; Ana María Espinosa-García; Laura Alejandra Ramírez-Tirado; Vicente Morales-Oyarvide; Carlos Rojas-Marín; Andrés-Felipe Cardona; Oscar Arrieta
Journal:  Am J Clin Oncol       Date:  2017-12       Impact factor: 2.339

Review 3.  Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.

Authors:  Jody C Chuang; Joel W Neal; Xiao-Min Niu; Heather A Wakelee
Journal:  Lung Cancer       Date:  2015-07-30       Impact factor: 5.705

4.  A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry.

Authors:  Mari Mino-Kenudson; Lucian R Chirieac; Kenny Law; Jason L Hornick; Neal Lindeman; Eugene J Mark; David W Cohen; Bruce E Johnson; Pasi A Jänne; A John Iafrate; Scott J Rodig
Journal:  Clin Cancer Res       Date:  2010-02-23       Impact factor: 12.531

5.  Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization.

Authors:  Jin Ho Paik; Gheeyoung Choe; Hyojin Kim; Ji-Young Choe; Hyun Ju Lee; Choon-Taek Lee; Jong Seok Lee; Sanghoon Jheon; Jin-Haeng Chung
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

Review 6.  The biology and treatment of EML4-ALK non-small cell lung cancer.

Authors:  Takaaki Sasaki; Scott J Rodig; Lucian R Chirieac; Pasi A Jänne
Journal:  Eur J Cancer       Date:  2010-04-24       Impact factor: 9.162

7.  Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended.

Authors:  Spasenija Savic; Joachim Diebold; Anne-Katrin Zimmermann; Wolfram Jochum; Betty Baschiera; Susanne Grieshaber; Luigi Tornillo; Bettina Bisig; Keith Kerr; Lukas Bubendorf
Journal:  Lung Cancer       Date:  2015-05-21       Impact factor: 5.705

8.  Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology.

Authors:  Neal I Lindeman; Philip T Cagle; Mary Beth Beasley; Dhananjay Arun Chitale; Sanja Dacic; Giuseppe Giaccone; Robert Brian Jenkins; David J Kwiatkowski; Juan-Sebastian Saldivar; Jeremy Squire; Erik Thunnissen; Marc Ladanyi
Journal:  J Mol Diagn       Date:  2013-04-04       Impact factor: 5.568

9.  Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.

Authors:  Ying Li; Yongwen Li; Tong Yang; Sen Wei; Jing Wang; Min Wang; Yuli Wang; Qinghua Zhou; Hongyu Liu; Jun Chen
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry.

Authors:  Esther Conde; Ana Suárez-Gauthier; Amparo Benito; Pilar Garrido; Rosario García-Campelo; Michele Biscuola; Luis Paz-Ares; David Hardisson; Javier de Castro; M Carmen Camacho; Delvys Rodriguez-Abreu; Ihab Abdulkader; Josep Ramirez; Noemí Reguart; Marta Salido; Lara Pijuán; Edurne Arriola; Julián Sanz; Victoria Folgueras; Noemí Villanueva; Javier Gómez-Román; Manuel Hidalgo; Fernando López-Ríos
Journal:  PLoS One       Date:  2014-09-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.